BE2016C011I2 - - Google Patents
Info
- Publication number
- BE2016C011I2 BE2016C011I2 BE2016C011C BE2016C011C BE2016C011I2 BE 2016C011 I2 BE2016C011 I2 BE 2016C011I2 BE 2016C011 C BE2016C011 C BE 2016C011C BE 2016C011 C BE2016C011 C BE 2016C011C BE 2016C011 I2 BE2016C011 I2 BE 2016C011I2
- Authority
- BE
- Belgium
- Prior art keywords
- hypertension
- diabetic
- renal
- pharmaceutically acceptable
- primary
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11389398A | 1998-07-10 | 1998-07-10 | |
EP99934647A EP1096932B1 (en) | 1998-07-10 | 1999-07-09 | Antihypertensive combination of valsartan and calcium channel blocker |
EP07105179A EP1870098A3 (en) | 1998-07-10 | 1999-07-09 | Combined use of valsartan and calcium channel blockers for therapeutic purposes |
Publications (1)
Publication Number | Publication Date |
---|---|
BE2016C011I2 true BE2016C011I2 (nl) | 2018-12-04 |
Family
ID=22352165
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BE2016C011C BE2016C011I2 (nl) | 1998-07-10 | 2016-03-07 |
Country Status (32)
Country | Link |
---|---|
EP (3) | EP2322174B1 (nl) |
JP (1) | JP2002520274A (nl) |
KR (2) | KR100550167B1 (nl) |
CN (2) | CN1234357C (nl) |
AT (1) | ATE371448T1 (nl) |
AU (1) | AU753486B2 (nl) |
BE (1) | BE2016C011I2 (nl) |
BR (1) | BR9912021A (nl) |
CA (2) | CA2678722C (nl) |
CY (4) | CY1107779T1 (nl) |
CZ (2) | CZ299429B6 (nl) |
DE (2) | DE122007000055I1 (nl) |
DK (2) | DK1096932T3 (nl) |
ES (2) | ES2289814T3 (nl) |
FR (1) | FR16C0008I2 (nl) |
HK (2) | HK1036758A1 (nl) |
HU (1) | HU229383B1 (nl) |
ID (1) | ID27664A (nl) |
IL (3) | IL140665A0 (nl) |
LU (2) | LU91358I2 (nl) |
NL (2) | NL300290I2 (nl) |
NO (2) | NO331802B1 (nl) |
NZ (2) | NZ509260A (nl) |
PL (1) | PL194604B1 (nl) |
PT (2) | PT1096932E (nl) |
RU (3) | RU2243768C2 (nl) |
SG (1) | SG142116A1 (nl) |
SI (2) | SI1096932T1 (nl) |
SK (1) | SK285863B6 (nl) |
TR (1) | TR200100062T2 (nl) |
WO (1) | WO2000002543A2 (nl) |
ZA (1) | ZA200100232B (nl) |
Families Citing this family (46)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2322174B1 (en) | 1998-07-10 | 2015-09-23 | Novartis Pharma AG | Combined use of valsartan and calcium channel blockers for therapeutic purposes |
KR100646716B1 (ko) * | 1998-12-23 | 2006-11-17 | 노파르티스 아게 | At-1 또는 at-2 수용체의 증가와 관련된 질환의치료에 있어서 at-1 수용체 길항제 또는 at-2 수용체조절제의 용도 |
ES2233362T3 (es) | 1999-04-28 | 2005-06-16 | Takeda Pharmaceutical Company Limited | Agentes para prevenir/tratar/inhibir el avance de retinopatia simple o retinopatia preproliferativa. |
JP2001089393A (ja) * | 1999-07-21 | 2001-04-03 | Takeda Chem Ind Ltd | 脳血管障害の再発予防剤および脳血管障害の後遺症の改善・進展抑制剤 |
SE9903028D0 (sv) * | 1999-08-27 | 1999-08-27 | Astra Ab | New use |
AU2001235363A1 (en) * | 2000-02-25 | 2001-09-03 | Novo-Nordisk A/S | Mibefradil analogues and their use |
AU2001235364A1 (en) * | 2000-02-25 | 2001-09-03 | Novo-Nordisk A/S | Tetrahydronaphtalene derivatives and their use |
MXPA02010091A (es) * | 2000-04-12 | 2003-02-12 | Novartis Ag | Novedoso uso medico de inhibidores de sintasa de aldosterona solos o en combinacion con antagonistas del receptor at-1. |
DE10018401A1 (de) * | 2000-04-13 | 2001-10-25 | Boehringer Ingelheim Pharma | Verwendung von Bradycardica bei der Behandlung von mit Hypertrophie einhergehenden Myocarderkrankungen und neue Arzneimittelkombinationen |
US20060089389A1 (en) | 2000-08-22 | 2006-04-27 | Malcolm Allison | Combination |
AR033390A1 (es) * | 2000-08-22 | 2003-12-17 | Novartis Ag | Una composicion farmaceutica que comprende un antagonista del receptor at1 y un potenciador de la secrecion de insulina, el uso de dicha composicion para la fabricacion de un medicamento y un kit de partes |
BR0108823A (pt) * | 2000-12-29 | 2002-12-10 | Osmotica Corp | Composição farmacêutica para o tratamento da doença cerebrovascular cognitiva |
ITMI20010129A1 (it) * | 2001-01-25 | 2002-07-25 | Pharmacia & Upjohn Spa | Acidi grassi essenziali nella terapia di insufficienza cardiaca e scompenso cardiaco |
EP1448190A2 (en) * | 2001-10-18 | 2004-08-25 | Novartis AG | Salts formed of an at1-receptor antagonist and a cardiovascular agent |
US20030180712A1 (en) * | 2002-03-20 | 2003-09-25 | Biostratum Ab | Inhibition of the beta3 subunit of L-type Ca2+ channels |
EG24716A (en) * | 2002-05-17 | 2010-06-07 | Novartis Ag | Combination of organic compounds |
US20040138306A1 (en) | 2002-07-25 | 2004-07-15 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Use of a specific cyclic amine derivative or the pharmaceutically acceptable salts thereof for the treatment or prevention of heart failure |
DE10335027A1 (de) * | 2003-07-31 | 2005-02-17 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Verwendung von Angiotensin II Rezeptor Antagonisten |
SE0300988D0 (sv) * | 2003-04-03 | 2003-04-03 | Astrazeneca Ab | New use |
ATE437641T1 (de) | 2003-05-15 | 2009-08-15 | Roskamp Res Llc | Verfahren zur herstellung von medikamenten zur verringerung der amyloid-abscheidung, amyloid- neurotoxizität und mikrogliosis |
EP1631556A1 (en) * | 2003-05-16 | 2006-03-08 | Novartis AG | Pharmaceutical composition comprising valsartan |
US20050065094A1 (en) | 2003-09-05 | 2005-03-24 | Boehringer Ingelheim International Gmbh | Use of telmisartan for the prevention and treatment of vascular headache |
WO2005053687A1 (en) * | 2003-11-25 | 2005-06-16 | Novartis Ag | Combination of organic compounds |
WO2005070463A2 (en) * | 2004-01-12 | 2005-08-04 | Sepracor, Inc. | Compositions comprising (s)-amlodipine malate and an angiotensin receptor blocker and methods of their use |
CN100364532C (zh) * | 2004-09-30 | 2008-01-30 | 江苏恒瑞医药股份有限公司 | 包含氨氯地平和血管紧张素ⅱ受体抑制剂的组合物 |
EP1874311B1 (en) | 2005-04-15 | 2011-10-05 | Research & Innovation S.p.A. | A method for preventing, delaying or reverting abnormal amyloid deposition |
GT200600371A (es) * | 2005-08-17 | 2007-03-21 | Formas de dosis sólidas de valsartan y amlodipina y método para hacer las mismas | |
GB0520405D0 (en) * | 2005-10-07 | 2005-11-16 | Imp College Innovations Ltd | Biological agents and method |
KR20080066776A (ko) * | 2005-11-08 | 2008-07-16 | 노파르티스 아게 | 안지오텐신 ⅱ 수용체 봉쇄제, 칼슘 채널 봉쇄제 및 다른활성 약제의 조합물 |
AR057882A1 (es) | 2005-11-09 | 2007-12-26 | Novartis Ag | Compuestos de accion doble de bloqueadores del receptor de angiotensina e inhibidores de endopeptidasa neutra |
KR100888131B1 (ko) * | 2006-10-10 | 2009-03-11 | 한올제약주식회사 | 시간차 투약 원리를 이용한 심혈관계 질환 치료용 복합제제 |
RU2490014C2 (ru) | 2007-10-05 | 2013-08-20 | Альцгеймер'С Инститьют Оф Америка, Инк. | Способ уменьшения отложения амилоида, амилоидной нейротоксичности и микроглиоза с помощью (-)-энантиомера нилвадипина |
CN101433536A (zh) * | 2007-11-12 | 2009-05-20 | 北京瑞康医药技术有限公司 | 含有烟酸氨氯地平和沙坦类药物的治疗组合物 |
EP2240163A1 (en) * | 2007-12-31 | 2010-10-20 | Lupin Limited | Pharmaceutical compositions of amlodipine and valsartan |
WO2010006103A1 (en) * | 2008-07-10 | 2010-01-14 | Ore Pharmaceuticals Inc. | Method for enhancing cognition or inhibiting cognitive decline |
WO2011102702A2 (en) | 2010-02-16 | 2011-08-25 | Krka, D. D., Novo Mesto | Process for the preparation of oral solid dosage forms comprising valsartan |
IT1400309B1 (it) | 2010-05-10 | 2013-05-24 | Menarini Int Operations Lu Sa | Associazione di inibitori della xantina ossidasi e calcio antagonisti e loro uso. |
SG194162A1 (en) * | 2011-04-12 | 2013-11-29 | Boryung Pharm | Antihypertensive pharmaceutical composition |
KR20140057604A (ko) | 2011-08-12 | 2014-05-13 | 베링거잉겔하임베트메디카게엠베하 | 고양잇과 동물의 심부전을 치료 및 예방하는 방법에 사용하기 위한 퍼니 전류 억제제 |
JPWO2013147137A1 (ja) * | 2012-03-30 | 2015-12-14 | 味の素株式会社 | 心不全の治療剤 |
CZ2013783A3 (cs) | 2013-10-08 | 2015-04-15 | Zentiva, K. S | Stabilní farmaceutická kompozice obsahující amlodipin a valsartan |
WO2016073179A2 (en) * | 2014-10-23 | 2016-05-12 | The Trustees Of The University Of Pennsylvania | Novel chronotherapy based on circadian rhythms |
RU2616213C2 (ru) * | 2015-07-10 | 2017-04-13 | Государственное бюджетное образовательное учреждение высшего профессионального образования "Южно-Уральский государственный медицинский университет" Министерства здравоохранения Российской Федерации (ГБОУ ВПО ЮУГМУ Минздрава России) | Способ коррекции дисфункции факторов врожденного и адаптивного иммунитета при хронической почечной недостаточности в эксперименте |
KR102489706B1 (ko) * | 2015-10-31 | 2023-01-17 | 아이오 테라퓨틱스, 인크. | Rxr 아고니스트와 갑상선 호르몬의 조합을 사용한 신경계 질환의 치료 |
CN105287550A (zh) * | 2015-11-19 | 2016-02-03 | 哈尔滨圣吉药业股份有限公司 | 一种缬沙坦/非洛地平复方制剂及其制备方法 |
WO2021239106A1 (zh) * | 2020-05-28 | 2021-12-02 | 杭州起岸生物科技有限公司 | 钾atp通道调节剂在制备抗糖尿病肾病药物中的应用 |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4654372A (en) * | 1986-01-10 | 1987-03-31 | Warner-Lambert Company | Method for using verapamil for treating stroke |
GB8608335D0 (en) | 1986-04-04 | 1986-05-08 | Pfizer Ltd | Pharmaceutically acceptable salts |
ES2084801T3 (es) * | 1990-02-19 | 1996-05-16 | Ciba Geigy Ag | Acil compuestos. |
NZ242724A (en) | 1991-05-15 | 1994-09-27 | Du Pont | Synergistic composition comprising an angiotensin-ii receptor antagonist and a calcium channel blocker |
US5492904A (en) * | 1991-05-15 | 1996-02-20 | E. I. Du Pont De Nemours And Company | Composition of angiotensin-II receptor antagonists and calcium channel blockers |
WO1993017682A1 (en) * | 1992-03-04 | 1993-09-16 | Abbott Laboratories | Angiotensin ii receptor antagonists |
NZ253611A (en) * | 1992-07-27 | 1996-09-25 | Pfizer | Polypeptide found in the venom of the agelenopsis spider and its use as a calcium channel blocker |
US5264447A (en) * | 1992-09-01 | 1993-11-23 | Merck & Co., Inc. | Angiotensin II antagonist |
US5721263A (en) * | 1993-06-07 | 1998-02-24 | Takeda Chemical Industries, Ltd. | Pharmaceutical composition for angiotensin II-mediated diseases |
CA2125251C (en) * | 1993-06-07 | 2005-04-26 | Yoshiyuki Inada | A pharmaceutical composition for angiotensin ii-mediated diseases |
EP0634175B1 (de) * | 1993-07-15 | 2001-01-10 | F. Hoffmann-La Roche Ag | Pharmazeutische Kombination, die einen Hemmer des Renin-Angiotensin-Systems und einen Endothelin-Antagonisten enthält |
JPH09508641A (ja) * | 1994-02-08 | 1997-09-02 | チバーガイギー アクチエンゲゼルシャフト | アンギオテンシン▲ii▼拮抗薬による正常眼圧緑内障の治療 |
WO1995024901A1 (en) | 1994-03-17 | 1995-09-21 | Ciba-Geigy Ag | Treatment of diabetic nephropathy with valsartan |
GB9613470D0 (en) | 1996-06-27 | 1996-08-28 | Ciba Geigy Ag | Small solid oral dosage form |
EP2322174B1 (en) | 1998-07-10 | 2015-09-23 | Novartis Pharma AG | Combined use of valsartan and calcium channel blockers for therapeutic purposes |
-
1999
- 1999-07-09 EP EP10177093.1A patent/EP2322174B1/en not_active Revoked
- 1999-07-09 CN CNB998097764A patent/CN1234357C/zh not_active Expired - Lifetime
- 1999-07-09 DK DK99934647T patent/DK1096932T3/da active
- 1999-07-09 KR KR1020017000323A patent/KR100550167B1/ko not_active IP Right Cessation
- 1999-07-09 IL IL14066599A patent/IL140665A0/xx unknown
- 1999-07-09 CZ CZ20010087A patent/CZ299429B6/cs unknown
- 1999-07-09 SK SK31-2001A patent/SK285863B6/sk not_active IP Right Cessation
- 1999-07-09 WO PCT/EP1999/004842 patent/WO2000002543A2/en active IP Right Grant
- 1999-07-09 CZ CZ2007-647A patent/CZ304359B6/cs not_active IP Right Cessation
- 1999-07-09 KR KR10-2004-7011566A patent/KR20040078140A/ko active Search and Examination
- 1999-07-09 EP EP99934647A patent/EP1096932B1/en not_active Revoked
- 1999-07-09 CN CNA200510072738XA patent/CN1733307A/zh active Pending
- 1999-07-09 CA CA2678722A patent/CA2678722C/en not_active Expired - Lifetime
- 1999-07-09 SG SG200300082-5A patent/SG142116A1/en unknown
- 1999-07-09 AT AT99934647T patent/ATE371448T1/de active
- 1999-07-09 NZ NZ509260A patent/NZ509260A/en not_active IP Right Cessation
- 1999-07-09 PL PL99345897A patent/PL194604B1/pl unknown
- 1999-07-09 RU RU2001102585/15K patent/RU2243768C2/ru active
- 1999-07-09 BR BR9912021-6A patent/BR9912021A/pt not_active IP Right Cessation
- 1999-07-09 ES ES99934647T patent/ES2289814T3/es not_active Expired - Lifetime
- 1999-07-09 ES ES10177093.1T patent/ES2552639T3/es not_active Expired - Lifetime
- 1999-07-09 JP JP2000558803A patent/JP2002520274A/ja active Pending
- 1999-07-09 PT PT99934647T patent/PT1096932E/pt unknown
- 1999-07-09 NZ NZ527598A patent/NZ527598A/xx not_active IP Right Cessation
- 1999-07-09 SI SI9930996T patent/SI1096932T1/sl unknown
- 1999-07-09 SI SI9931078T patent/SI2322174T1/sl unknown
- 1999-07-09 DE DE200712000055 patent/DE122007000055I1/de active Pending
- 1999-07-09 EP EP07105179A patent/EP1870098A3/en not_active Withdrawn
- 1999-07-09 ID IDW20010051A patent/ID27664A/id unknown
- 1999-07-09 DK DK10177093.1T patent/DK2322174T3/en active
- 1999-07-09 CA CA002336822A patent/CA2336822C/en not_active Expired - Lifetime
- 1999-07-09 AU AU50349/99A patent/AU753486B2/en not_active Expired
- 1999-07-09 DE DE69936992T patent/DE69936992T2/de not_active Expired - Lifetime
- 1999-07-09 PT PT101770931T patent/PT2322174E/pt unknown
- 1999-07-09 TR TR2001/00062T patent/TR200100062T2/xx unknown
- 1999-07-09 RU RU2001102585/15A patent/RU2450813C2/ru active Protection Beyond IP Right Term
- 1999-07-09 HU HU0102828A patent/HU229383B1/hu active Protection Beyond IP Right Term
-
2001
- 2001-01-01 IL IL140665A patent/IL140665A/en unknown
- 2001-01-08 NO NO20010113A patent/NO331802B1/no not_active IP Right Cessation
- 2001-01-09 ZA ZA200100232A patent/ZA200100232B/en unknown
- 2001-11-02 HK HK01107697A patent/HK1036758A1/xx not_active IP Right Cessation
-
2007
- 2007-09-06 LU LU91358C patent/LU91358I2/fr unknown
- 2007-09-10 NL NL300290C patent/NL300290I2/nl unknown
- 2007-10-25 CY CY20071101384T patent/CY1107779T1/el unknown
- 2007-10-30 CY CY200700026C patent/CY2007026I1/el unknown
-
2011
- 2011-07-04 IL IL213926A patent/IL213926A0/en unknown
- 2011-07-11 HK HK11107161.5A patent/HK1152897A1/xx not_active IP Right Cessation
-
2012
- 2012-03-20 RU RU2012110522/15A patent/RU2012110522A/ru unknown
- 2012-07-03 NO NO2012013C patent/NO2012013I2/no unknown
-
2015
- 2015-10-06 CY CY20151100890T patent/CY1116770T1/el unknown
-
2016
- 2016-03-07 LU LU92992C patent/LU92992I2/xx unknown
- 2016-03-07 CY CY2016006C patent/CY2016006I1/el unknown
- 2016-03-07 FR FR16C0008C patent/FR16C0008I2/fr active Active
- 2016-03-07 NL NL300800C patent/NL300800I2/nl unknown
- 2016-03-07 BE BE2016C011C patent/BE2016C011I2/nl unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
FR16C0008I1 (nl) | ||
NL300811I2 (nl) |